Bostock IC, Alberú J, Salazar-Nando A, Huante-Pérez A, Cervantes M, León-García D, Figueroa-Granados V, Gabilondo B, Morales-Buenrostro LE, Vilatobá CM, Soto-Ramírez LE

Language: Spanish
References: 12
Page: 15-19
PDF size: 72.57 Kb.

ABSTRACT

The prevalence of human herpes virus-8 antibodies has a great geographic variability in the general population and in pre- and post-kidney transplant recipients, and is associated with the development of Kaposi’s sarcoma. In Mexico, human herpes virus-8 seroprevalence in 307 blood donors was 0.65%. Aim: To investigate: 1) human herpes virus-8 seroprevalence, and 2) associated risk factors for seropositivity, in a) 156 chronic renal failure patients (pts) randomly selected from a waiting list for cadaveric transplantation, and b) 118 kidney transplant recipients with functioning grafts at diverse post-Kidney transplant follow up. Methods: Demographic data were obtained for kidney transplant recipients from clinical files and by a self-administered questionnaire for sexual practices; in chronic renal failure pts, data were obtained by direct interview. Serum samples from all pts were tested for IgG antibodies using an ELISA commercial kit. Data analyzed: chronic renal failure group: mean age 36 ± 13 years, 50% male, overall mean time on dialysis 43 ± 47 mos (20.5% hemodialysis, 56% CAPD, 18.6% both, 5 none), blood transfusion history (BT) 78%, previous kidney transplant 9%. Kidney transplant recipients group: mean age 30 ± 11 years, 55% male, mean time post-kidney transplant follow up 111 ± 70 mos, pre-kidney transplant overall time on dialysis 22 ± 21.8 mos (37% hemodialysis, 35.6% CAPD, 23% both, 4% none), blood transfusion 79%, triple drug immunosuppressive therapy 76%. Results: human herpes virus-8 IgG antibodies were detected in 6/156 (3.8%) and in 4/118 (3.4%) chronic renal failure and kidney transplant recipients patients, respectively. There were no risk factors significantly associated with human herpes virus-8 antibodies in the chronic renal failure group. However, in kidney transplant recipients patients, multivariate analysis demonstrated hemodialysis to be a significant risk factor (p = 0.03), and a blood transfusion showed a trend towards statistical significance (p = 0.06); on the other hand, by univariate analysis a blood transfusion was a significant risk factor (p = 0.04), and hemodialysis showed a trend (p = 0.089). Conclusions: Chronic renal failure patients, regardless of having received a kidney transplant, had a high risk for human herpes virus-8 infection (› 5 times of the prevalence among healthy blood donors). The exposure to blood products was a risk factor for this infection in kidney transplant recipients; the lack of significance of this factor in chronic renal failure group could be related to the low number of infected pts studied. Although the kidney transplant recipients studied remain free of Kaposi’s sarcoma, they should be closely monitored.

REFERENCES

1. Regamey N, Tamm M, Wernli M et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339: 1358-63.

2. Francès C, Mouquet C, Marcelin AG. Outcome of kidney transplant recipients with previous human herpesvirus 8 infection. Transplantation 2000; 69: 1776-9.

3. Farge D, Lebbé C, Marjanovic Z et al. Human herpes virus 8 and other risk factors for Kaposi’s sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d’ Ile de France (GCIF). Transplantation 1999; 67: 1236-42.

4. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet 1996; 348: 858-61.

5. Soto-Ramírez LE, Salazar A, Figueroa-Granados V et al. Risk factors for human herpesvirus 8 (HHV-8) seropositivity in chronic renal failure patients on a waiting list for transplant and in kidney transplant recipients. Transplantation 2002; 74 (suppl): Abstract 2955.

6. Gomes PS, Boschiroli AM, Machado PGP et al. Human herpesvirus 8 seroprevalence in kidney transplant patients in Brazil: Evaluation of ELISA and Imunofluorescence methods for antibody detection. Transplantation 2002; 74 (suppl): Abstract 2954.

7. Campistol JM, Cuervas-Mons V, Manito N et al. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Reviews (Orlando) 2012; 26: 261-79.

8. Berber I, Altaca G, Aydin C et al. Kaposi’s sarcoma in renal transplant patients: predisposing factors and prognosis. Transplant Proc 2005; 37: 967-8.

9. Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol 2006; 44: 27-32.

10. Regamey N, Tamm M, Wernli M et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339: 1358-63.

11. Marcelin AG, Roque-Afonso AM, Hurtova M et al. Fatal disseminated Kaposi’s sarcoma following human herpesvirus primary infections in liver-transplant recipients. Liver Transpl 2004; 10: 295-300.

12. Francès C, Marcelin AG, Legendre Ch et al. The impact of preexisting or acquired Kaposi sarcoma herpes virus infection in kidney transplant recipients on morbidity and survival. American J Transplant 2009; 9: 2580-6.